OVCA2

Summary

OVCA2 (OVCA2 serine hydrolase domain containing, HGNC:24203) is a protein-coding gene on chromosome 17p13.3, encoding Esterase OVCA2 (Q8WZ82). Exhibits ester hydrolase activity with a strong preference for long-chain alkyl ester substrates and high selectivity against a variety of short, branched, and substituted esters.

Predicted to enable hydrolase activity. Involved in response to retinoic acid. Located in cytoplasm. Biomarker of ovarian cancer.

Source: NCBI Gene 124641 — RefSeq curated summary.

At a glance

• GWAS associations: 2
• Clinical variants (ClinVar): 1 total
• MANE Select transcript: NM_080822

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:24203
Approved symbol	OVCA2
Name	OVCA2 serine hydrolase domain containing
Location	17p13.3
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000262664
Ensembl biotype	protein_coding
OMIM	607896
Entrez	124641

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 protein_coding

ENST00000572195

RefSeq mRNA: 1 — MANE Select: NM_080822 NM_080822

CCDS: CCDS11015

Canonical transcript exons

ENST00000572195 — 2 exons

Exon	Start	End
ENSE00002650423	2042022	2042231
ENSE00003672537	2042605	2043425

Expression profiles

Bgee: expression breadth ubiquitous, 133 present calls, max score 93.45.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 35.2061 / max 153.8171, expressed in 1824 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
158800	32.8619	1822
158802	1.6822	1099
158801	0.6620	384

Top tissues by expression

133 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
mucosa of transverse colon	UBERON:0004991	93.45	gold quality
right adrenal gland	UBERON:0001233	92.41	gold quality
right adrenal gland cortex	UBERON:0035827	92.28	gold quality
left adrenal gland	UBERON:0001234	92.08	gold quality
granulocyte	CL:0000094	91.98	gold quality
adenohypophysis	UBERON:0002196	91.96	gold quality
lower esophagus mucosa	UBERON:0035834	91.87	gold quality
left adrenal gland cortex	UBERON:0035825	91.75	gold quality
pituitary gland	UBERON:0000007	91.65	gold quality
right lobe of liver	UBERON:0001114	90.85	gold quality
esophagus mucosa	UBERON:0002469	90.76	gold quality
apex of heart	UBERON:0002098	90.57	gold quality
body of stomach	UBERON:0001161	90.37	gold quality
adult mammalian kidney	UBERON:0000082	90.35	gold quality
adrenal gland	UBERON:0002369	90.11	gold quality
spleen	UBERON:0002106	89.65	gold quality
lymph node	UBERON:0000029	89.57	gold quality
gastrocnemius	UBERON:0001388	89.52	gold quality
hindlimb stylopod muscle	UBERON:0004252	89.51	gold quality
skin of leg	UBERON:0001511	89.39	gold quality
body of pancreas	UBERON:0001150	89.36	gold quality
skin of abdomen	UBERON:0001416	89.29	gold quality
esophagus	UBERON:0001043	89.23	gold quality
left testis	UBERON:0004533	89.18	gold quality
right testis	UBERON:0004534	89.15	gold quality
zone of skin	UBERON:0000014	89.12	gold quality
transverse colon	UBERON:0001157	89.11	gold quality
leukocyte	CL:0000738	89.09	gold quality
heart left ventricle	UBERON:0002084	89.03	gold quality
muscle of leg	UBERON:0001383	88.93	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

23 targeting OVCA2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-513B-5P	99.99	69.96	2150
HSA-MIR-4487	99.96	64.58	1252
HSA-MIR-3912-5P	99.95	66.11	925
HSA-MIR-6744-5P	99.93	66.82	748
HSA-MIR-4728-5P	99.85	69.39	4718
HSA-MIR-6785-5P	99.82	68.68	4428
HSA-MIR-149-3P	99.72	68.22	3963
HSA-MIR-6883-5P	99.69	68.05	3785
HSA-MIR-513C-5P	99.50	68.42	1730
HSA-MIR-514B-5P	99.50	68.19	1766
HSA-MIR-6081	99.48	66.07	1446
HSA-MIR-4667-3P	99.26	65.45	1608
HSA-MIR-4710	98.61	65.96	1048
HSA-MIR-6818-3P	98.56	68.23	1307
HSA-MIR-224-5P	98.33	70.12	1256
HSA-MIR-197-3P	98.09	69.23	1004
HSA-MIR-6865-3P	97.54	64.67	684
HSA-MIR-3194-5P	96.80	64.90	1027
HSA-MIR-582-3P	96.69	67.38	1019
HSA-MIR-125B-2-3P	96.69	68.38	1210
HSA-MIR-3139	96.68	66.77	652
HSA-MIR-6851-3P	95.73	65.11	688
HSA-MIR-6879-3P	93.93	64.00	759

Literature-anchored findings (GeneRIF, showing 3)

• is downregulated and degraded during retinoid-induced apoptosis (PMID:11979432)
• OVCA2 was confirmed as a serine hydrolase with a strong preference for long-chain alkyl ester substrates (>10-carbons) and high selectivity against a variety of short, branched, and substituted esters, homologous to FSH1 from S. cerevisiae (PMID:32182256)
• Human OVCA2 and its homolog FSH3-induced apoptosis in Saccharomyces cerevisiae. (PMID:33715035)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	ovca2	ENSDARG00000103748
mus_musculus	Ovca2	ENSMUSG00000038268
rattus_norvegicus	Ovca2	ENSRNOG00000082594
drosophila_melanogaster	CG5412	FBGN0038806
caenorhabditis_elegans		WBGENE00007730

Protein

Protein identifiers

Esterase OVCA2 — Q8WZ82 (reviewed: Q8WZ82)

Alternative names: OVCA2 serine hydrolase domain-containing protein, Ovarian cancer-associated gene 2 protein

All UniProt accessions (1): Q8WZ82

UniProt curated annotations — full annotation on UniProt →

Function. Exhibits ester hydrolase activity with a strong preference for long-chain alkyl ester substrates and high selectivity against a variety of short, branched, and substituted esters. Is able to hydrolyze ester bonds within a wide range of p-nitrophenyl derivatives (C2-C14) in vitro, with a strong preference toward substrates of >8 carbons.

Tissue specificity. Ubiquitously expressed.

Post-translational modifications. Proteolytically degraded in response to RA and 4HPR treatment in a time- and dose-dependent manner in the promyelocytic leukemia cell line HL-60.

Similarity. Belongs to the LovG family.

RefSeq proteins (1): NP_543012* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR005645	FSH-like_dom	Domain
IPR029058	AB_hydrolase_fold	Homologous_superfamily
IPR050593	LovG	Family

Pfam: PF03959

Catalyzed reactions (Rhea), 1 shown:

• a carboxylic ester + H2O = an alcohol + a carboxylate + H(+) (RHEA:21164)

UniProt features (10 total): active site 3, mutagenesis site 3, sequence conflict 2, chain 1, region of interest 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8WZ82-F1	91.03	0.83

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (3): 119 (charge relay system); 179 (charge relay system); 206 (charge relay system)

Mutagenesis-validated functional residues (3):

Position	Phenotype
119	abolishes the hydrolase activity against long chain alkyl ester substrates.
179	reduces the hydrolase activity against long chain alkyl ester substrates.
206	abolishes the hydrolase activity against long chain alkyl ester substrates.

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 40 (showing top): GOBP_RESPONSE_TO_OXYGEN_CONTAINING_COMPOUND, GOBP_RESPONSE_TO_LIPID, GOBP_RESPONSE_TO_RETINOIC_ACID, SCGGAAGY_ELK1_02, GOMF_HYDROLASE_ACTIVITY_ACTING_ON_ESTER_BONDS, GOMF_CARBOXYLIC_ESTER_HYDROLASE_ACTIVITY, FEV_TARGET_GENES, HOXC6_TARGET_GENES, ID1_TARGET_GENES, SETD7_TARGET_GENES, ZSCAN31_TARGET_GENES, GSE10239_KLRG1INT_VS_KLRG1HIGH_EFF_CD8_TCELL_UP, MARTORIATI_MDM4_TARGETS_FETAL_LIVER_DN, BLANCO_MELO_INFLUENZA_A_INFECTION_A594_CELLS_DN, GSE17721_LPS_VS_PAM3CSK4_24H_BMDC_UP

GO Biological Process (1): response to retinoic acid (GO:0032526)

GO Molecular Function (3): hydrolase activity (GO:0016787), carboxylesterase activity (GO:0106435), carboxylic ester hydrolase activity (GO:0052689)

GO Cellular Component (3): nucleus (GO:0005634), cytoplasm (GO:0005737), mitochondrion (GO:0005739)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
intracellular membrane-bounded organelle	2
response to lipid	1
response to oxygen-containing compound	1
catalytic activity	1
carboxylic ester hydrolase activity	1
hydrolase activity, acting on ester bonds	1
intracellular anatomical structure	1
cellular anatomical structure	1
cytoplasm	1

Protein interactions and networks

STRING

538 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
OVCA2	DPH1	Q9BZG8	932
OVCA2	DPH2	Q9BQC3	683
OVCA2	NXPH2	O95156	543
OVCA2	SEPTIN9	Q9UHD8	497
OVCA2	C11orf98	E9PRG8	447
OVCA2	ABHD10	Q9NUJ1	443
OVCA2	DPH5	Q9H2P9	424
OVCA2	BPHL	Q86WA6	412
OVCA2	IAH1	Q2TAA2	401
OVCA2	HIC1	Q14526	400
OVCA2	SIAE	Q9HAT2	396
OVCA2	IFNA16	P05015	386
OVCA2	IFNA7	P01567	385
OVCA2	IFNA8	P01565	385
OVCA2	IFNA14	P01570	385
OVCA2	IFNA21	P01568	385
OVCA2	PAFAH1B2	P68402	385

IntAct

4 interactions, top by confidence:

A	B	Type	Score
OVCA2	MYH11	psi-mi:“MI:0914”(association)	0.530
INSR	RIMOC1	psi-mi:“MI:0914”(association)	0.350

BioGRID (11): MYH11 (Affinity Capture-MS), PTPN11 (Affinity Capture-MS), MYH11 (Affinity Capture-MS), PTPN11 (Affinity Capture-MS), PTPN11 (Affinity Capture-MS), MYH11 (Affinity Capture-MS), OVCA2 (Co-fractionation), OVCA2 (Co-fractionation), OVCA2 (Affinity Capture-MS), OVCA2 (Affinity Capture-MS), OVCA2 (Co-fractionation)

ESM2 similar proteins: A4II73, A5WVX1, A6QLY4, O16216, O18391, O55137, O55171, P34913, P80299, Q07G10, Q0C7C4, Q0J7N5, Q0V9K2, Q18169, Q29LW1, Q2TAA2, Q2TAP9, Q3SZ07, Q3SZ16, Q3SZ73, Q3ZC52, Q503Y4, Q5JUR7, Q5RCH4, Q5RDV8, Q61YZ4, Q653S9, Q6AXU8, Q6I7R3, Q6ING7, Q6Q2C2, Q711G3, Q7QBJ0, Q7ZY31, Q80UN9, Q8BVH9, Q8HY87, Q8R123, Q8VDG5, Q8WZ82

Diamond homologs: A0A0A2JY30, C8VJR6, Q8WZ82, A0A0D2YG06, A0A1L7TZY0, A0A348HAY8, Q18169, Q3SZ07, Q503Y4, Q9D7E3, S0DRW4, S0EES1, W7MT28, W7MWX7, A4II73, O13897, P36591, Q05015, Q0C7C4, Q29BR3, Q61YZ4, Q7QBJ0, Q94AC1, Q99369, Q9VDL1, A0A161CKG1, A0A1P8VFN0, A0A481WP25, A0A5B8YVD7, A0A5C1RHX3, B8M9K3, G3XMB7, N4WQZ8, Q0C8M2, Q0CF71, Q0CS97, Q1ERH9, Q5AUY1, Q5BEJ8, Q8J0F8

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

1 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	0
Likely benign	0
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

287 predictions. Top by Δscore:

Variant	Effect	Δscore
17:2042137:G:GT	donor_gain	1.0000
17:2042228:TTCGG:T	donor_loss	0.9900
17:2042232:GT:G	donor_loss	0.9900
17:2042233:T:G	donor_loss	0.9900
17:2042603:AG:A	acceptor_gain	0.9900
17:2042604:GG:G	acceptor_gain	0.9900
17:2042232:G:GG	donor_gain	0.9800
17:2042234:GA:G	donor_loss	0.9700
17:2042138:A:T	donor_gain	0.9600
17:2042233:T:C	donor_loss	0.9600
17:2042040:C:A	acceptor_gain	0.9500
17:2042600:TGTA:T	acceptor_loss	0.9500
17:2042601:GTA:G	acceptor_loss	0.9500
17:2042602:TA:T	acceptor_loss	0.9500
17:2042604:G:GT	acceptor_loss	0.9500
17:2042679:G:GT	donor_gain	0.9500
17:2042594:T:G	acceptor_gain	0.9400
17:2042603:A:AG	acceptor_gain	0.9400
17:2042604:G:GG	acceptor_gain	0.9400
17:2042593:ATATC:A	acceptor_gain	0.9300
17:2042235:A:AC	donor_loss	0.9200
17:2042597:C:A	acceptor_loss	0.9200
17:2042601:GTAG:G	acceptor_loss	0.9200
17:2042603:AGGGT:A	acceptor_loss	0.9200
17:2042604:GGGT:G	acceptor_gain	0.9200
17:2042604:GGGTC:G	acceptor_gain	0.9100
17:2042595:ATC:A	acceptor_gain	0.9000
17:2042120:A:T	donor_gain	0.8800
17:2042252:G:GT	donor_gain	0.8800
17:2042597:C:CA	acceptor_gain	0.8800

AlphaMissense

1446 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
17:2042772:T:C	F118L	0.998
17:2042774:C:A	F118L	0.998
17:2042774:C:G	F118L	0.998
17:2042776:G:T	S119I	0.997
17:2042871:T:C	F151L	0.996
17:2042873:C:A	F151L	0.996
17:2042873:C:G	F151L	0.996
17:2042955:G:C	D179H	0.996
17:2043038:C:A	H206Q	0.995
17:2043038:C:G	H206Q	0.995
17:2042956:A:T	D179V	0.994
17:2042773:T:C	F118S	0.993
17:2042781:G:T	G121W	0.993
17:2043036:C:G	H206D	0.993
17:2042776:G:A	S119N	0.992
17:2042090:T:C	F15L	0.991
17:2042092:C:A	F15L	0.991
17:2042092:C:G	F15L	0.991
17:2042775:A:C	S119R	0.991
17:2042777:C:A	S119R	0.991
17:2042777:C:G	S119R	0.991
17:2042941:T:A	V174D	0.991
17:2042956:A:C	D179A	0.991
17:2042955:G:T	D179Y	0.990
17:2042637:T:A	W73R	0.988
17:2042637:T:C	W73R	0.988
17:2042947:G:A	G176E	0.988
17:2042643:T:C	F75L	0.986
17:2042645:T:A	F75L	0.986
17:2042645:T:G	F75L	0.986

dbSNP variants (sampled 300 via entrez): RS1000112259 (17:2042402 C>G,T), RS1000148954 (17:2043466 T>G), RS1000201625 (17:2043215 C>G), RS1000484055 (17:2042483 A>C), RS1001146133 (17:2041581 A>C,G), RS1002207231 (17:2041604 C>T), RS1002536085 (17:2040437 A>T), RS1005920163 (17:2041029 T>C), RS1006335647 (17:2042115 G>A,C), RS1006429559 (17:2041335 G>A,C), RS1006669505 (17:2041160 G>A), RS1007057377 (17:2040893 C>T), RS1007345223 (17:2041772 A>C,G), RS1007876660 (17:2043205 C>G), RS1008341463 (17:2040078 G>A,T)

Disease associations

OMIM: gene MIM:607896 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST002875_126	Diisocyanate-induced asthma	1.000000e-06
GCST010703_278	Brain morphology (MOSTest)	2.000000e-15

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0006995	response to diisocyanate
EFO:0004346	neuroimaging measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

14 total (human), top 14 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
aristolochic acid I	decreases expression	1
fluorene-9-bisphenol	decreases expression	1
ethyl-p-hydroxybenzoate	increases expression	1
ferrous chloride	decreases expression	1
CGP 52608	increases reaction, affects binding	1
Acetaldehyde	increases response to substance	1
Atrazine	increases expression	1
Diazinon	increases methylation	1
Doxorubicin	decreases expression	1
Ivermectin	decreases expression	1
Smoke	decreases expression	1
Dronabinol	decreases expression	1
Valproic Acid	increases methylation	1
Copper Sulfate	decreases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.